Obesity Affects Respiration in Women

Results from a new cross-sectional study published in Respiratory Medicine provide evidence that obesity is associated with adverse respiratory symptoms in women, but the same correlation was not observed in men.


 

Because obesity is a known risk factor for higher rates of new and worsening respiratory diseases such as asthma and chronic obstructive pulmonary disorder (COPD), Swedish researchers set out to investigate the association between abdominal and general obesity with respiratory symptom severity in asthma and COPD in adult men and women.

Design

The Swedish study relied on patient data from the Respiratory Health in Northern Europe (RHINE) III questionnaire, which contained the health records of 12,290 individuals over two years, from 2010 to 2012. The self-reported questionnaire included questions such as ‘Have you had an asthma attack in the last 12 months?’ and ‘Do you usually cough up mucus in the chest that is hard to get out?’ The study also used self-reported body mass index (BMI), where general obesity was defined as BMI โ‰ฅ30kg/m2 and abdominal obesity was defined as a waist circumference (WC) of โ‰ฅ 102cm in men and โ‰ฅ88cm in women.

Results

This graph demonstrates the overlap between general and abdominal obesity in study participants.

Of the participant data used, it was found that 34.7% had abdominal obesity, 6.7% had general obesity, and 13.6% had both abdominal and general obesity (see graph). Both abdominal and general obesity were independently associated with respiratory symptoms with an odds ratio (OR) of 1.25 to 2.00 in both adult women and men. Asthma was significantly associated with abdominal obesity (OR, 1.56; 95% CI, 1.30-1.87; Pย = .052) and general obesity (OR, 1.95; 95% CI, 1.56-2.43; P = .006), respectively, in women, but not in men. Similarly, COPD was significantly associated with abdominal obesity (OR, 1.62; 95% CI, 1.15-2.28;ย Pย = .02) and general obesity (OR, 2.87; 95% CI, 2.00-4.10;ย P = .001), respectively, in women, but not in men.

Limitations

The study was based on a self-reported questionnaire, but the researchers believe that their results provide a clearer picture when treating female patients with respiratory symptoms and obesity. It is also notable that abdominal obesity was more common in the women who participated, while the men who responded had higher rates of general obesity than women. This gender-specific observance, specifically the link between abdominal adipose tissue and breathing issues in women, may be worthy of further exploration. Lastly, the researchers identified three lifestyle factors (smoking, education, and physical activity level) as possible confounding variables in their study.

Discussion and Takeaway

The clinical relevance of the correlation uncovered by Dr. Kisiel and his colleagues may result in providers measuring WC in addition to height and weight when seeing patients with respiratory symptoms. The researchers concluded their publication by stating that both general and abdominal obesity independent of each other were associated with respiratory symptoms, but “for self-reported asthma and COPD, a significant association with abdominal and general obesity was found in women but not men. Measuring waist circumference can be important when seeing patients with respiratory symptoms. General and abdominal obesity were independent factors associated with respiratory symptoms. Asthma and COPD disease were independently linked to abdominal and general obesity in women but not men.”

โ€œThe main result of this study was that both general and abdominal obesity were independently associated with respiratory symptoms in adults. However, asthma and COPD were significantly associated with abdominal and general obesity in women only.โ€ – Kisiel, et al.

 

Source

  • Kisiel MA, Arnfelt O, Lindberg E, et al. Association between abdominal and general obesity and respiratory symptoms, asthma and COPD, results from the Rhine study. Respiratory Medicine. 2023;211:107213. doi:10.1016/j.rmed.2023.107213
More Articles
Why Should We Use CGM in Patients With Type 2 Diabetes?
This clinical brief was developed from a session at the 17th Annual Cardiometabolic Health Congress (CMHC) presented by Irl B…
Should Diabetes Management be More Adipose-Centric?
This complimentary activity was developed by Neha Agarwal, PhD,  Senior Clinical Manager for Cardiometabolic Health…
Sanofi Joins Lilly and Novo to Cut Insulin Prices
Sanofi was the last of three pharmaceutical goliaths to announce theyโ€™d make good on their long-spoken promise to lower the…
Lilly Cuts Insulin Prices

In an era when health care and pharmaceutical prices continue to trend upwards, Eli Lilly made a historic announcement on Wednesday, March 1, 2023, stating that they would be reducing prices of their most commonly prescribed insulins by 70% and expanding their Insulin Value Program capping out-of-pocket costs at $35 or less per month for most patients.

The History of Insulin

The origins of insulin track back to 1889, when two German researchers, Oskar Minkowski and Joseph von Mering, found that when the pancreas gland was removed from dogs they developed symptoms of diabetes. Inย 1910, Sir Edward Albert Sharpey-Shafer determined that only one chemical was missing from the pancreas in people with diabetes: insulin.

Then, in 1921, Frederick Banting and his assistant Charles Best discovered how to remove just insulin from a dogโ€™s pancreas. Colleagues J.B. Collip and John Maclead took this discovery one step further, and developed a more refined and purer form of insulin, this time from the pancreases of cattle. One year later, a young boy dying from diabetes became the first person to receive an insulin injection; within 24 hours of the injection, 14-year old Leonard Thompsonโ€™s dangerously high blood glucose levels dropped to near-normal levels.

The news spread quickly, and in 1923, Banting and Macleod received the Nobel Prize in Medicine and the use of insulin became widespread. Although Banting refused to sell the patent for insulin because he felt it was unethical for a doctor to profit from its lifesaving properties, Collip and Best sold the insulin patent for just $1, saying they “wanted everyone who needed the medication to be able to afford it.”

The word insulin comes from the Latin word…
Latest Blogs

Subscribe

Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.